Print

Purpose

The purpose of this study is to determine whether patients with acute kidney injury requiring renal replacement therapy have a higher incidence of muscle wasting than controls and whether the course of recovery is longer compared to controls.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 89 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • >18 years old - AKI requiring CRRT, with enrollment within 48 hours of CRRT initiation

Exclusion Criteria

  • ICU admission for >7 days - RRT of any kind at any time prior to ICU admission - Chronic kidney disease (CKD) with estimated glomerular filtration rate <20 mL/min/1.73 m2 as calculated by the 2021 CKD-EPI equation - underlying muscle disorders or muscle atrophy such as quadriplegia or hemiplegia, stroke with residual motor deficits, end-stage liver disease, active alcohol use disorder, active malignancy (other than non-melanoma skin cancer) within 1 year, burns, or other baseline neuromuscular disease - pregnancy - concomitant use of other extracorporeal support devices such as ventricular assist devices or extracorporeal membrane oxygenation - anticipated inability to engage in weight-bearing testing after discharge (e.g., trauma or orthopedic surgery) - subjects will be ineligible for outpatient testing if they remain on RRT in the week prior to the research appointment

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
AKI-RRT Adults admitted to the ICU with AKI requiring CRRT with study enrollment within 48 hours of CRRT initiation.
  • Diagnostic Test: Musculoskeletal ultrasound
    Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
  • Diagnostic Test: Assessments of muscle strength and physical function
    A battery of tests of physical function and muscle strength (see outcomes section for details).
  • Diagnostic Test: Metabolomics
    Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
Historical Controls The controls for the ICU phase will be 41 critically ill adults without AKI-RRT in whom similar measurements of muscle size, quality, and function were collected in a recent prior study [PubMed ID: 33148301]. The controls for the recovery phase will come from an ongoing prospective observational study being performed at the University of Kentucky, which will include outpatient functional assessments performed on 200 ICU survivors (NCT05537298).
  • Diagnostic Test: Musculoskeletal ultrasound
    Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
  • Diagnostic Test: Assessments of muscle strength and physical function
    A battery of tests of physical function and muscle strength (see outcomes section for details).

Recruiting Locations

More Details

NCT ID
NCT05287204
Status
Active, not recruiting
Sponsor
University of Iowa

Detailed Description

Acute kidney injury (AKI), the abrupt loss of kidney function, is a common complication that affects more than half of all intensive care unit (ICU) admissions, and it is associated with substantially higher rates of morbidity and mortality in both the short- and the long-term. This is especially true in patients with AKI requiring renal replacement therapy (AKI-RRT), also known as dialysis. An understudied mechanism by which AKI-RRT may contribute to poor clinical outcomes, both in the hospital and after discharge, is through its impact on muscle mass and muscle function. AKI of any severity is known to alter tissue utilization of amino acids, and preliminary data suggest that RRT in the ICU may exacerbate muscle dysfunction through the removal of large quantities of amino acids from the patient's plasma. This study will determine whether patients with AKI-RRT have greater lean muscle loss over 1 week than historical critically ill controls, whether patients with AKI-RRT have diminished recovery of muscle mass and function at 1-3 months following discharge compared to controls, and whether changes in plasma levels of amino acids during hospitalization correlate with loss of muscle function or lack of recovery.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.